MinervaX is pursuing the development of a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threating infections caused by Group B streptococcus (GBS). The vaccine is based on adjuvanted proteins antigens covering close to 100% of clinical GBS isolates. Group B Streptococcal (GBS) is the leading cause of life-threatening infections in newborns. Colonization of pregnant women with GBS may lead to adverse pregnancy outcomes such as late abortions, stillbirths, and preterm delivery. Colonization may also lead to life-threatening infections in newborns for the first 3 months of life, causing pneumonia, septicemia and meningitis, which may lead to death or life-long disability. Annually, GBS is responsible for some 320,000 cases of neonatal invasive disease, 60,000 stillbirths, 3,500,000 preterm deliveries, and 10,000 babies suffering from long-term neurological damage world-wide.
View Top Employees from Minervax ApSWebsite | http://www.minervax.com |
Revenue | $5 million |
Employees | 50 (28 on RocketReach) |
Founded | 2010 |
Address | 28 Vedbendvej, Hellerup, Region Hovedstaden 2900, DK |
Phone | (453) 267-3287 |
Technologies |
JavaScript,
HTML,
PHP
+8 more
(view full list)
|
Industry | Biotechnology, Health Care, Drug Discovery, Pharmaceuticals, Medical, Healthcare |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325414 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies |
Looking for a particular Minervax ApS employee's phone or email?
The Minervax ApS annual revenue was $5 million in 2024.
Bo Henriksen is the CFO of Minervax ApS.
28 people are employed at Minervax ApS.
Minervax ApS is based in Hellerup, Region Hovedstaden.
The NAICS codes for Minervax ApS are [325414, 32, 3254, 325, 32541].
The SIC codes for Minervax ApS are [283, 28].